Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
By Nicole Longo | December 21, 2020
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical...
Read More
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
By Nicole Longo | December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...
Read More
Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements
By Nicole Longo | December 15, 2020
In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the...
Read More
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
By Nicole Longo | December 10, 2020
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to...
Read More
No matter how you look at it, the Most Favored Nation rule is bad policy
By Nicole Longo | December 1, 2020
Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access...
Read More
Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D
By Nicole Longo | November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...
Read More
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
By Nicole Longo | November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...
Read More
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
By Nicole Longo | October 23, 2020
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...
Read More
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
By Nicole Longo | October 13, 2020
In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today,...
Read More
Growth in 340B program has not translated to improvements for patients
By Nicole Longo | October 5, 2020
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program....
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
